checkAd

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

Nachrichtenquelle: globenewswire
08.04.2021, 22:01  |  109   |   |   

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021.

Details for the poster presentations are as follows:

ONC201: Characterization and combinatorial efficacy in brain tumors

Title: ADME and toxicology profiles of first-in-class DRD2/ClpP-targeted imipridone ONC201
Abstract Number: 1370
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Sara Morrow, M.S., Chimerix
Session Title: Pharmacology, Pharmacogenetics, and Pharmacogenomics

Title: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG)
Abstract Number: 635
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Robyn Borsuk, M.D., Warren Alpert Medical School, Brown University
Session Title: Pediatric Cancer: Clinical Investigations

Title: The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell lines
Abstract Number: 1156
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Yiqun Zhang, Ph.D., Warren Alpert Medical School, Brown University
Session Title: HDAC and Methyltransferase Inhibitors

ONC201: Combinatorial efficacy in other solid tumors

Title: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death
Abstract Number: 1060
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Wen-I Chang, M.D., Warren Alpert Medical School, Brown University
Session Title: Combination Therapies

Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors of apoptosis and up-regulation of DR5 in gastric adenocarcinoma
Abstract Number: 1044
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Cassandra Parker, M.D., Warren Alpert Medical School, Brown University
Session Title: Combination Therapies

Title: Imipridones exhibit synergy with sorafenib, HDAC inhibition, PARP inhibition, and proteasome inhibition in liver cancer cell lines
Abstract Number: 1040
Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT
Presenter: Joshua Honeyman, M.D., Warren Alpert Medical School, Brown University

Seite 1 von 2
Chimerix Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel